Rafael Holdings (RFL) AI Stock Analysis

• Market Cap: $70.42M
• Dividend Yield: N/A
• Average Volume (3M): 155.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 35.56%
• EPS Growth: 21.87%
• Country: US
• Employees: 28
• Sector: Real Estate
• Sector Strength: 53
• Industry: Real Estate - Services
• EPS (TTM): -0.28
• Shares Outstanding: 50,983,643
• 10 Day Avg. Volume: 97,875
• 30 Day Avg. Volume: 155,838
• PEG Ratio: 0.06
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 54.22
• P/FCF Ratio: -2.63
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: 7.17
• Enterprise Value/Gross Profit: 8.86
• Enterprise Value/Ebitda: -0.20
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: $1.50 ▲(10.29% Upside)

Rafael Holdings faces significant challenges with profitability and cash flow, which are the most impactful factors on its overall score. The technical analysis indicates a bearish trend, and the valuation is weak due to negative earnings and lack of dividends. These factors collectively result in a low overall stock score.

Rafael Holdings Business Overview & Revenue Model

Company Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

How the Company Makes Money

Rafael Holdings generates revenue through its biopharmaceutical operations, particularly by developing and potentially commercializing drug candidates that target various forms of cancer. The company may receive milestone payments and royalties from partnerships with larger pharmaceutical companies for the development and commercialization of its therapies. Additionally, Rafael Holdings has a portfolio of real estate assets that contribute to its revenue through leasing and property management activities. The combination of these revenue streams, alongside strategic collaborations and partnerships in the pharmaceutical industry, underpins the company's financial performance.

Rafael Holdings Financial Statement Overview

Summary

Rafael Holdings shows strong revenue growth and gross profit margins, but faces significant profitability and cash flow challenges. The balance sheet is robust with low leverage, yet the negative return on equity highlights inefficiencies. Overall, while there are strengths in revenue and equity management, the company must address its profitability and cash flow issues to improve its financial health.

Income Statement

Rafael Holdings shows a strong gross profit margin of 88.44% for the latest year, indicating efficient cost management. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -33.28% and negative EBIT and EBITDA margins. Revenue growth is positive at 25.27%, but the persistent losses highlight significant challenges in achieving sustainable profitability.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.007, suggesting minimal leverage risk. However, the return on equity is negative at -32.33%, indicating that the company is not generating returns on its equity investments. The equity ratio is healthy, but the negative ROE points to inefficiencies in asset utilization.

Cash Flow

Cash flow analysis reveals a concerning trend with negative operating cash flow and free cash flow. Despite a significant free cash flow growth rate of 65.14%, the operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive, suggesting some alignment between cash flow and accounting profits.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	917.00K	917.00K	637.00K	279.00K	410.00K	3.97M
Gross Profit	742.00K	811.00K	483.00K	201.00K	338.00K	3.90M
EBITDA	-32.25M	-32.25M	-66.79M	-8.67M	-139.89M	-23.34M
Net Income	-30.52M	-30.52M	-34.41M	-1.88M	-124.66M	-25.15M
Balance Sheet
Total Assets	114.11M	114.11M	96.83M	98.83M	118.32M	154.06M
Cash, Cash Equivalents and Short-Term Investments	52.77M	52.77M	65.94M	79.51M	63.23M	7.85M
Total Debt	692.00K	692.00K	2.39M	0.00	15.00M	14.53M
Total Liabilities	15.74M	15.74M	10.57M	2.20M	21.11M	17.35M
Stockholders Equity	94.39M	94.39M	82.19M	100.29M	100.52M	122.29M
Cash Flow
Free Cash Flow	-18.92M	-18.93M	-7.95M	40.79M	-26.08M	-15.81M
Operating Cash Flow	-18.93M	-18.92M	-7.80M	-10.89M	-26.08M	-15.60M
Investing Cash Flow	44.03M	44.03M	-10.82M	21.21M	-63.80M	-8.17M
Financing Cash Flow	24.83M	24.83M	-179.00K	-15.22M	103.86M	30.30M

Rafael Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RFL, the sentiment is Neutral. The current price of 1.36 is above the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.39, and below the 200-day MA of 1.69, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.50 is Neutral, neither overbought nor oversold. The STOCH value of 26.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RFL.

Rafael Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
FTHM	―	$53.72M	―	-50.22%	―	19.16%	12.99%
OPAD	―	$71.57M	―	-111.30%	―	-30.44%	15.55%
RFL	―	$70.42M	-1.33	-27.47%	―	35.56%	21.87%
STHO	―	$98.88M	1.44	-18.83%	―	-13.95%	37.24%

Rafael Holdings Corporate Events

Rafael Holdings Reports 2025 Financial Results and Strategic Progress

Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage pharmaceutical and medical device companies. The company’s lead candidate, Trappsol® Cyclo™, is undergoing a pivotal Phase 3 clinical trial for treating Niemann-Pick Disease Type C1, a rare genetic disorder.

Rafael Holdings Appoints Alan Grayson to Board

On October 23, 2025, Rafael Holdings announced the appointment of Alan Grayson to its Board of Directors, following the passing of Stephen Greenberg, the Lead Independent Director. Grayson, a former Member of Congress and experienced attorney, will serve on several committees, while Markus Sieger, an existing board member, was appointed as Chair of the Audit Committee and Lead Independent Director. These changes aim to fill the leadership void left by Greenberg’s passing and strengthen the company’s governance structure.

Rafael Holdings Announces Executive Team Changes

On August 4, 2025, Rafael Holdings announced changes in its executive team, with John Goldberg resigning as Chief Medical Officer effective July 31, 2025, and Joshua Fine being elected as the new Chief Operating Officer. Joshua Fine, who has a background in finance and operations, will receive a salary increase and stock options as part of his new role. Additionally, a General Release Agreement was entered with N. Scott Fine, providing a severance payment and continued vesting of equity, while Dr. Goldberg will receive severance and stock shares in lieu of a performance bonus, alongside a consulting agreement.